Urol. praxi. 2022;23(1):23-26 | DOI: 10.36290/uro.2021.036

Small renal masses: contemporary trends in management approach

MUDr. Lukáš Gaduš1, 2, MUDr. Darina Pacigová1, MUDr. Kamil Belej, Ph.D., FEBU, MBA1, 3
1 Urologické oddělení, Ústřední vojenská nemocnice - Vojenská fakultní nemocnice, Praha
2 1. lékařská fakulta, Univerzita Karlova, Praha
3 Urologická klinika, 1. lékařská fakulta, Univerzita Karlova, Praha

Small renal masses which are defined as tumours smaller than 4 cm represent a subset of renal tumours with low malignant and metastatic potential. They are commonly diagnosed incidentally in an asymptomatic stage on abdominal ultrasound, CT or MRI examination which are performed for another indication. The management of small renal mass is individual. The main treatment is surgical resection of renal mass, the alternative is focal ablation of the tumour. Active surveillance remains for a highly selected group of patients. Percutaneous renal mass biopsy is recommended prior to tumour focal ablation and should be considered in patients undergoing active surveillance.

Keywords: small renal mass, focal ablation, nephrectomy, partial nephrecomy, active surveillance.

Received: November 8, 2021; Revised: December 15, 2021; Accepted: December 27, 2021; Prepublished online: December 27, 2021; Published: March 16, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Gaduš L, Pacigová D, Belej K. Small renal masses: contemporary trends in management approach. Urol. praxi. 2022;23(1):23-26. doi: 10.36290/uro.2021.036.
Download citation

References

  1. Gill IS, Aron M, Gervais DA, et al. Clinical practice. Small renal mass. N Engl J Med. 2010;362(7):624-634. Go to original source... Go to PubMed...
  2. Campbell SC, Novick AC, Belldegrun A, et al. Guideline for management of the clinical T1 renal mass. J Urol. 2009;182(4): 1271-1279. Go to original source... Go to PubMed...
  3. Almassi N, Gill BC, Rini B, et al. Management of the small renal mass. Transl Androl Urol. 2017;6(5):923-930. Go to original source... Go to PubMed...
  4. Frank I, Blute ML, Cheville JC, et al. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003;170(6):2217-2220. Go to original source... Go to PubMed...
  5. Wilcox Vanden Berg RN, Basourakos SP, LaRussa S, et al. Management of the small renal mass: a 2020 Update. Curr Oncol Rep. 2020;22(7):69. Go to original source... Go to PubMed...
  6. Khiatani V, Dixon RG. Renal ablation update. Semin Interv Radiol. 2014;31(2):157-166. Go to original source... Go to PubMed...
  7. Čermák A, Pacík D, Vít V. Současný pohled na léčbu malých nádorů ledvin. Urol List. 2012;10(3):6-15.
  8. Sugimura K, Ikemoto SI, Kawashima H, et al. Microscopic hematuria as a screening marker for urinary tract malignancies. Int J Urol. 2001;8(1):1-5. Go to original source... Go to PubMed...
  9. Israel GM, Bosniak MA. Pitfalls in renal mass evaluation and how to avoid them. Radiographics. 2008;28(5):1325-1338. Go to original source... Go to PubMed...
  10. Voss J, Drake T, Matthews H, et al. Chest computed tomography for staging renal tumours: validation and simplification of a risk prediction model from a large contemporary retrospective cohort. BJU Int. 2020;125(4):561-567. Go to original source... Go to PubMed...
  11. Fan L, Lianfang D, Jinfang X, et al. Diagnostic efficacy of contrast­‑enhanced ultrasonography in solid renal parenchymal lesions with maximum diameters of 5 cm. J Ultrasound Med. 2008;27(6):875-885. Go to original source... Go to PubMed...
  12. Johnson BA, Kim S, Steinberg RL, et al. Diagnostic performance of prospectively assigned clear cell Likelihood scores (ccLS) in small renal masses at multiparametric magnetic resonance imaging. Urol Oncol. 2019;37(12):941-946. Go to original source... Go to PubMed...
  13. Marconi L, Dabestani S, Lam TB, et al. Systematic review and meta­‑analysis of diagnostic accuracy of percutaneous renal tumour biopsy. Eur Urol. 2016;69(4):660-673. Go to original source... Go to PubMed...
  14. Tøndel C, Vikse BE, Bostad L et al. Safety and complications of percutaneous kidney biopsies in 715 children and 8573 adults in Norway 1988-2010. Clin J Am Soc Nephrol. 2012;7(10):1591-1597. Go to original source... Go to PubMed...
  15. Chang DTS, Sur H, Lozinskiy M, et al. Needle tract seeding following percutaneous biopsy of renal cell carcinoma. Korean J Urol. 2015;56(9):666-669. Go to original source... Go to PubMed...
  16. Ljungberg B, Albiges L., Bedkeet J, et al. EAU Guidelines on Renal Cell Carcinoma. EAU Guidelines 2021. https://uroweb.org/guideline/renal­‑cell­‑carcinoma/.
  17. Mason RJ, Abdolell M, Trottier G, et al. Growth kinetics of renal masses: analysis of a prospective cohort of patients undergoing active surveillance. Eur Urol. 2011;59(5):863-867. Go to original source... Go to PubMed...
  18. Thompson RH, Hill J, Babayev Y, et al. Risk of metastatic renal cell carcinoma according to tumor size. J Urol. 2009;182(1):41-45. Go to original source... Go to PubMed...
  19. Krabbe LM, Bagrodia A, Margulis V, et al. Surgical management of renal cell carcinoma. Semin Interv Radiol. 2014;31(1): 27-32. Go to original source... Go to PubMed...
  20. Portis AJ, Yan Y, Jaime L, et al. Long­‑term followup after laparoscopic radical nephrectomy. J Urol. 2002;167(3):1257-1262. Go to original source... Go to PubMed...
  21. Peyronnet B, Seisen T, Oger E, et al. Comparison of 1800 robotic and open partial nephrectomies for renal tumors. Ann Surg Oncol. 2016;23(13):4277-4283. Go to original source... Go to PubMed...
  22. Choi JE, You JH, Kim DK, et al. Comparison of perioperative outcomes between robotic and laparoscopic partial nephrectomy: a systematic review and meta­‑analysis. Eur Urol. 2015;67(5):891-901. Go to original source... Go to PubMed...
  23. Gaduš L, Heráček J, Pacigová D, et al. Indocyaninová zeleň v urologické praxi: doporučení a využití při resekci ledviny. Urol. praxi. 2021;22(1):9-12. Go to original source...




Urology for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.